Gammadelta T cells in cancer immunotherapy

Dr. Bank is a physician and immunologist, involved in research in the field of gammadelta T cells since 1986 . His scientific career henceforth included studies contributing to definition of the role of gammadelta T cells in autoimmune, infectious and malignant conditions in humans. Regarding the latter, his laboratory was among the first to show anti breast cancer activity of human gammadelta T cells, and later also their mechanisms of activity against glioblastoma. Most recently, his group participated in creation of anti lymphoma CAR (anti CD20) bearing human gammadelta T cells and reported preclinical efficacy., He has been editor of a topic on Gammadelta T cells in cancer including 11 papers published in Frontiers of Immunology and an active participant and organizer in the biannual gammadelta T cell meetings, and has been invited to chair the immunotherapy session in the upcoming meeting in Lisbon , 2023 Dieter Kabelitz is full professor at the University of Kiel, Germany, and Director of the Institute of Immunology. Dieter Kabelitz studied medicine in Freiburg and Munich, Germany. He was a post-doc in Uppsala/Sweden and at Rockefeller University, New York. In 1988, he was appointed Associate Professor for Cellular Immunology at the University of Heidelberg. From 1992 to 1999 he was Head of the Department of Immunology at the Paul-Ehrlich Institute in Langen, Germany. Since 1999 he is a full professor at the University of Kiel and Director of the Institute of Immunology. His scientific expertise is in the field of the functional characterization of human T cells with a special focus on ?? T cells. Current projects aim to explore the potential of human ?? T cells for the immunotherapy of cancer. He has published more than 360 papers listed in PubMed/Medline. Dieter Kabelitz was chairman of the Collaborative Research Center (SFB) 415 „Specificity and Pathophysiology of Signal Transduction Pathways“ funded at Kiel University by the German Research Foundation (DFG). He is a founding member and member of the Steering Committee of the DFG-funded Cluster of Excellence „Inflammation-at-Interfaces“. He was President of the German Society for Immunology (DGfI) in 2011 and 2012, and he is a Council member of the International Union of Immunological Societies (IUIS) and chair of the Education Committee (EDU) of IUIS.

Chapter 1 The rationale for use of gd T cells in immunotherapy.

Chapter 2 Tissue derived gammadelta T cells as vehicles for cancer immunotherapy

Chapter 3 DOT-1 gammadelta T cell immunotherapeutic strategies. 4

Chapter 4 Allogeneic Vg9Vd2 T cells treatment for solid tumors.

Chapter 5 Gammadelta T cell receptor therapeutic reagents; mechanisms and applications

Chapter 6 Immunotherapy based on bispecific antibodies targeting Vg9+ gd TCR and tumor antigens.

Chapter 7 . Intratumoral Allogeneic gammadelta T cell therapy for glioblastoma multiforme

Chapter 8 Allogeneic CAR expressing Vd1+ gammadelta T cells for lymphoma and hepatocellular carcinoma

Chapter 9 Activating Monoclonal antibodies directed against butyrophilin ligands of Vg9Vd2+ gammadelta T cells for cancer immunotherapy

Chapter 10 Pro tumoral gammadelta T cells and their implication for immunotherapy.

Chapter 11 Overcoming hurdles of gammadelta T cell immunotherapeutics

Chapter 12 Increasing efficacy of gammadelta immunotherapy by targeted modulation of tumor phosphoantigens.

Chapter 13 Summary and conclusions